Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06136585 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Sugammadex Vs Neostigmine in Reversing Neuromuscular Blocks in Outpatient ERCP. A Randomized, Double-Blinded Trial

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Oct 31, 2025 to Oct 31, 2026
    • Study completion date: Dec 31, 2025 to Dec 31, 2026
    • Study description revised
    • Study site revised
    v9
  2. Phase: Not applicable to Phase 3
    • Study completion date: Oct 31, 2025 to Dec 31, 2025
    v8
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of May 15, 2024 to Jun 1, 2024
    v7
  4. Start date: Apr 1, 2024 to May 15, 2024v6
  5. Start date: Mar 1, 2024 to Apr 1, 2024v5
Show 3 earlier versionsHide 3 earlier versions
  1. Start date: Feb 1, 2024 to Mar 1, 2024v4
  2. Start date: Jan 1, 2024 to Feb 1, 2024v3
  3. Start date: Dec 1, 2023 to Jan 1, 2024
    • Study description expanded, about 1 word
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The investigators propose a single-center, assessor-Blinded, parallel group randomized trial to compare the efficacy of reversal of rocuronium induced neuromuscular blockade by sugammadex versus neostigmine in patients undergoing Endoscopic retrograde cholangiopancreatography at Cleveland Clinic Fairview Hospital.
Trial Details
NCT Number NCT06136585
Lead Sponsor The Cleveland Clinic
Collaborators: Merck Sharp & Dohme LLC
Conditions
(from sponsor)		 Neuromuscular Blocks
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov